Skip to content
OpenCapital
Get started

Harrow HROW Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$7.96M-63.4%
National Vision Holdings, Inc. logo
National Vision Holdings, Inc.EYE
——
Viatris logo
ViatrisVTRS
——

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%
Enterprise value$1.8B+13.8%
P/S5.9×+0.5×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: Harrow’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's indefinite-lived research and development assets?
Harrow (HROW) reported indefinite-lived research and development assets of $100K in Q4 2025.
What does indefinite-lived research and development assets mean?
This metric represents the carrying value of acquired in-process research and development projects that have not yet reached technological feasibility or regulatory approval. These assets are classified as indefinite-lived because they are not subject to amortization until the underlying products are successfully commercialized or abandoned. Investors monitor this balance to assess the company's investment in future product pipelines and the potential for future impairment risks if development milestones are not met.